Aleksandra Drelich
Overview
Explore the profile of Aleksandra Drelich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liao Y, Ma H, Wang Z, Wang S, He Y, Chang Y, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(6):e2406659122.
PMID: 39908098
The rapid evolution of the viral genome has led to the continual generation of new variants of SARS-CoV-2. Developing antibody drugs with broad-spectrum and high efficiency is a long-term task....
2.
Kumar V, Zhu J, Chenna B, Hoffpauir Z, Rademacher A, Rogers A, et al.
J Am Chem Soc
. 2025 Jan;
147(2):1631-1648.
PMID: 39746101
SARS-CoV-2 3CL protease (Main protease) and human cathepsin L are proteases that play unique roles in the infection of human cells by SARS-CoV-2, the causative agent of COVID-19. Both proteases...
3.
Song I, Washington M, Leynes C, Hsu J, Rayavara K, Bae Y, et al.
Mamm Genome
. 2024 Mar;
35(2):113-121.
PMID: 38488938
The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) remains a public health concern and a subject of active research effort. Development of pre-clinical animal models is critical to study viral-host interaction,...
4.
Westberg M, Su Y, Zou X, Huang P, Rustagi A, Garhyan J, et al.
Sci Transl Med
. 2024 Mar;
16(738):eadi0979.
PMID: 38478629
Inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M) such as nirmatrelvir (NTV) and ensitrelvir (ETV) have proven effective in reducing the severity of COVID-19, but...
5.
Yu B, Drelich A, Hsu J, Tat V, Peng B, Wei Q, et al.
J Med Chem
. 2023 Dec;
66(24):16646-16657.
PMID: 38100534
Enduring occurrence of severe COVID-19 for unvaccinated, aged, or immunocompromised individuals remains an urgent need. Soluble human angiotensin-converting enzyme 2 (ACE2) has been used as a decoy receptor to inhibit...
6.
Calvier L, Drelich A, Hsu J, Tseng C, Mina Y, Nath A, et al.
Front Immunol
. 2023 Jul;
14:1185748.
PMID: 37441066
Thromboembolic complications and excessive inflammation are frequent in severe COVID-19, potentially leading to long COVID. In non-COVID studies, we and others demonstrated that circulating Reelin promotes leukocyte infiltration and thrombosis....
7.
Xing J, Shankar R, Ko M, Zhang K, Zhang S, Drelich A, et al.
iScience
. 2022 Sep;
25(10):105068.
PMID: 36093376
The molecular manifestations of host cells responding to SARS-CoV-2 and its evolving variants of infection are vastly different across the studied models and conditions, imposing challenges for host-based antiviral drug...
8.
Mudrick H, Massey S, McGlinch E, Parrett B, Hemsath J, Barry M, et al.
Sci Adv
. 2022 Aug;
8(34):eabm8563.
PMID: 36001674
Most gene-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are nonreplicating vectors. They deliver the gene or messenger RNA to the cell to express the spike protein but do...
9.
Zhu J, Jain S, Sha J, Batra H, Ananthaswamy N, Kilgore P, et al.
mBio
. 2022 Jul;
13(4):e0182222.
PMID: 35900097
The U.S. Food and Drug Administration-authorized mRNA- and adenovirus-based SARS-CoV-2 vaccines are intramuscularly injected in two doses and effective in preventing COVID-19, but they do not induce efficient mucosal immunity...
10.
Zhu J, Li L, Drelich A, Chenna B, Mellott D, Taylor Z, et al.
Front Chem
. 2022 Jul;
10:867928.
PMID: 35860632
Cysteine proteases comprise an important class of drug targets, especially for infectious diseases such as Chagas disease (cruzain) and COVID-19 (3CL protease, cathepsin L). Peptide aldehydes have proven to be...